Phase 2 Trial Evaluating LUM-201 for Treatment of Growth Hormone Deficiency
Pisit “Duke” Pitukcheewanont, MD, Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 for treatment of growth hormone deficiency.
Related Articles
Working on the Frontlines of a Revolution in Multiple Myeloma Care
A Mayo Clinic “lifer” who did not consider medicine as a career path until his later teenage years grew into a powerhouse who touched nearly…
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Nature Medicine – In the TRACERx cohort of 171 patients with lung cancer, the ultrasensitive detection of ctDNA improves preoperative patient stratification, also in early-stage…
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
The safety of fedratinib as a maintenance strategy after alloSCT for MPNs: Phase I results
Hany Elmariah, MD, MS, Moffitt Cancer Center, Tampa, FL, presents the findings of a Phase I study (NCT05127174) investigating the safety of fedratinib as a…
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
PURPOSEOver the past 15 years, the landscape of early phase clinical trials (EPCTs) has undergone a remarkable expansion in both quantity and intricacy. The proliferation…
Transparency and Consolidation Issues Hamper 340B Program in Cancer Care
Since it’s implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and…
Preparation is Key to Tackle the Transition from Fellow to Attending Physician
A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.
Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care
Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.
Abstracts
Learn more about and submit your abstract to the AACR Annual Meeting 2025, held April 25-30, 2025, in Chicago, Illinois.
Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.